Dr Papadakis gave a presentation on how CRY’s research has impacted the investigation and management of people with conditions that can cause sudden cardiac death. After the presentation, there was a Q&A session

Dr Michael Papadakis has been a key member of the CRY team for years after first joining the charity when he started his training as a CRY Research Fellow in 2007. He’s continued to develop education in the sports cardiology field by building educational material for the European Society of Cardiology (ESC) and launched a novel degree in sports cardiology, which was the first post graduate qualification of its kind. Dr Papadakis has also transformed CRY’s myheart network. He serves

Former CRY Research Fellow Dr Chris Miles’ recent research helped demonstrate how new computer software can help identify and analyse abnormalities in the heart that we may not be able to see otherwise. Dr Miles’ paper, entitled “Morphometric characterization of collagen and fat in normal ventricular myocardium” (Miles C, Westaby J, Ster I C, et al. Cardiovascular Pathology, May, 2020), looked at 29 non-cardiac death cases referred to the CRY Centre for Cardiac Pathology. This study aimed to examine the

Former CRY Research Fellow Dr Gherado Finocchiaro completed a study into hypertrophic cardiomyopathy (HCM), aiming to determine the incidence of HCM in first-degree relatives of decedents from sudden death with idiopathic left ventricular hypertrophy. The paper, entitled “Diagnostic yield of hypertrophic cardiomyopathy in first-degree relatives of decedents with idiopathic left ventricular hypertrophy” (Finocchiaro G et al. Europace) was published in August 2020, and Dr Finocchiaro provided us with an explanation of what the study involved and some of the key

Former CRY Research Fellow Dr Lynne Millar recently completed a study into dilated cardiomyopathy in athletes, entitled “Differentiation between athlete’s heart and dilated cardiomyopathy in athletic individuals” (Millar L, Fanton Z, Finocchiaro G, et al. Heart, July 2020). This paper intended to distinguish the difference between dilated cardiomyopathy and typical, healthy changes that can occur in an athlete’s heart, and came up with an array of tests to help achieve this. This research is best explained by Dr Millar herself:

Professor Sharma spoke about how CRY’s research has impacted the way we look after families after a young sudden cardiac death as well as the way it has influenced the way we screen young people.

Webinar Recording: Guidance for ‘Safe Exercise’ in the COVID-era & How to prepare for a return to sport Agenda Introductions – Dr Steven Cox Exercise in the COVID-19 era; Facts and fiction – Professor Sanjay Sharma Going back to exercise; A roadmap to re-training – Professor Mathew Wilson Cardiac evaluation prior to returning to sport; One size fits all? – Dr Michael Papadakis

Basu J Malhotra A Papadakis M Exercise and hypertrophic cardiomyopathy: Two incompatible entities? Clinical Cardiology, February 2020 {Paper} A greater understanding of the pathogenic mechanisms underpinning hypertrophic cardiomyopathy (HCM) has translated to improved medical care and better survival of affected individuals. Historically these patients were considered to be at high risk of sudden cardiac death (SCD) during exercise; therefore, exercise recommendations were highly conservative and promoted a sedentary life style. There is emerging evidence that suggests that exercise in HCM